Over the past 20 years, obesity research has resulted in a better understanding of the complex disease mechanisms underlying the condition, including biological, behavioural, societal and environmental factors. Although obesity research in the past 10 years has resulted in very effective and safe obesity treatments, more research is needed to improve the lives of people with obesity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Blüher, M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288–298 (2019).
Rubino, F. et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 13, 221–262 (2025).
Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994).
Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug. Discov. 21, 201–223 (2022).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013).
Jastreboff, A. M. et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 392, 958–971 (2025).
Kühnen, P. et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N. Engl. J. Med. 375, 240–246 (2016).
Carlsson, L. M. S. et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects Study. N. Engl. J. Med. 383, 1535–1543 (2020).
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.B. received honoraria as a consultant and speaker from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis and Sanofi.
Rights and permissions
About this article
Cite this article
Blüher, M. The past and future of obesity research. Nat Rev Endocrinol 21, 666–667 (2025). https://doi.org/10.1038/s41574-025-01172-2
Published:
Issue date:
DOI: https://doi.org/10.1038/s41574-025-01172-2